Browse studies

Find your next paid study

8 recruiting studies matching your filters

ADVANCE-01: A Phase 1 Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML

This is a phase I, open-label, non-randomized clinical trial that will enroll pediatric and adult research participants with CLEC2A+ acute myeloid leukemia (AM…

Acute Myeloid LeukemiaAcute Myeloid Leukaemia RecurrentAcute Myeloid Leukaemia Refractory

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Seattle Children's HospitalNCT07905027

Phase 1

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally a…

Acute Lymphoblastic LeukaemiaAcute Myeloid LeukaemiaHigher-risk Myelodysplastic Syndromes

Estimated

~$150 – $4,500

Actual pay is set by the research site.

AstraZenecaNCT07155226

Phase 2

A Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in Acute Myeloid Leukemia Maintenance.

To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CR…

Acute Myeloid Leukaemia (AML)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Rutgers, The State University of New JerseyNCT07867626

Phase 2

A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination With Cytarabine Injection Versus Placebo in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed Acute Myeloid Leukemia

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for re…

Acute Myeloid Leukaemia (AML)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Moleculin Biotech, Inc.NCT06788756

Phase 2

Evaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia

This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC)…

Acute Myeloid Leukemia (AML)Acute Myeloid Leukaemia (AML)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

The Methodist Hospital Research InstituteNCT07060001

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (mult…

Acute Myeloid Leukaemia (AML)Follicular Lymphoma ( FL)

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Tempus AINCT07154823

Phase 1

A Phase 1, Open-Label, Multi-Centre Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-883 Monotherapy in Participants With Acute Myeloid Leukaemia and High-Risk Myelodysplastic Syndrome and in Combination With Anticancer Agents in Participants With Acute Myeloid Leukaemia

The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemi…

Acute Myeloid LeukaemiaHigh Risk Myelodysplastic Syndrome

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Amphista Therapeutics LtdNCT07723703

Phase 1

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Lef…

Acute Myeloid Leukaemia (AML)LeukemiaBlood Cancer+1 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Jacqueline Garcia, MDNCT07148180